Technical Analysis for CELG - Celgene Corporation

Grade Last Price % Change $ Change
grade D $115.22 0.23% 0.27
CELG closed up 0.23 percent on Wednesday, January 18, 2017, on 82 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Earnings due: 2017-01-26

Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Down
See historical CELG trend table...

Date Alert Name Type % Chg
Jan 18 NR7 Range Contraction 0.00%
Jan 18 Narrow Range Bar Range Contraction 0.00%
Jan 18 Bollinger Band Squeeze Range Contraction 0.00%
Jan 17 Fell Below 50 DMA Bearish 0.23%
Jan 17 Bollinger Band Squeeze Range Contraction 0.23%
Jan 13 Bollinger Band Squeeze Range Contraction -1.92%
Jan 13 50 DMA Support Bullish -1.92%
Jan 12 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -1.59%
Jan 12 Bollinger Band Squeeze Range Contraction -1.59%
Jan 12 50 DMA Support Bullish -1.59%

Older signals for CELG ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.

Profile
Celgene Corporation discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. Its commercial stage products include REVLIMID, a drug to treat multiple myeloma and transfusion-dependent anemia; VIDAZA, a nucleoside analog to treat intermediate-2 and myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML); ABRAXANE, a chemotherapy treatment option for metastatic breast cancer; and THALOMID for multiple myeloma and the cutaneous manifestations of erythema nodosum leprosum. The company’s commercial stage products also comprise ISTODAX to treat cutaneous T-cell lymphoma; POMALYST for the multiple myeloma and myelofibrosis treatment; and FOCALIN, FOCALIN XR, and RITALIN LA products. Its pre clinical and clinical stage products consist of CC-11050, an anti-inflammatory compound; CC-220, an anti-inflammatory product; cellular therapies, such as PDA-001 and PDA-002; CC-486 that is in Phase III trials to treat MDS and AML, as well as in a Phase I trials for solid tumor indications; and sotatercept and ACE-536, which are in Phase II trials to treat anemia. The company’s pre clinical and clinical stage products also include CC-223, a dual TORK inhibitor; CC-292, a BTK inhibitor; CC-115, a dual TORK/DNA PK inhibitor; CC-122, a pleiotropic pathway modulator; and EPZ-5676, a DOT1L inhibitor. It has strategic collaborations with bluebird bio, Inc.; FORMA Therapeutics Holdings; Concert Pharmaceuticals, Inc.; Array BioPharma, Inc.; and Acetylon Pharmaceuticals, Inc., as well as a strategic alliance with MorphoSys AG. The company was founded in 1980 and is headquartered in Summit, New Jersey.
Is CELG a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 127.0
52 Week Low 93.05
Average Volume 4,923,949
200-Day Moving Average 108.29
50-Day Moving Average 117.47
20-Day Moving Average 117.63
10-Day Moving Average 117.91
Average True Range 2.71
ADX 12.68
+DI 18.97
-DI: 28.03
Chandelier Exit (Long, 3 ATRs) 114.26
Chandelier Exit (Short, 3 ATRs) 121.28
Upper Bollinger Band 120.68
Lower Bollinger Band 114.58
Percent B (%b) 0.1
Bandwidth 0.051858